Rapid mobilisation to advance COVID-19 vaccine development

In February of this year, ICON quickly mobilised its vaccine and infectious disease resources to assist government and commercial clients in addressing the COVID-19 global threat.

One client trial investigating a prophylactic vaccine study in healthy participants required rapid patient recruitment, site selection, and study start-up.

• Close collaboration and responsiveness: The sponsor provided ICON an opportunity to review the draft protocol and provide comment. Our team reviewed the protocol and provide feedback including how the study would be monitored operationally within 1 business day
• Dedicated Clinical Trial Managers (CTMs): Enabling rapid responses to sponsor including the sponsor’s request to add 2 new sites (already selected) without advance notice. ICON was ready to initiate the new sites within 3 business days
• Dedicated cross-trained Clinical Research Associates (CRAs): Facilitating rapid resource shifts to adapt to changing sponsor priorities. CRA team was assigned, trained on the protocol / study procedures, and deployed to sites within 48 hours
• Expedited study start-up: The original site selected for the study was contacted, internal study team training completed, and everything was in place for an onsite visit within 10 business days. While it was postponed by the sponsor due to a forthcoming protocol amendment, the visit was conducted seamlessly and efficiently

• 3 sites planned
• 45 participants
• US only